We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Products Facilitate Sample Enrichment for Next-Generation Sequencing Protocols

By LabMedica International staff writers
Posted on 16 Oct 2012
A new line of products that enables the enrichment of the whole exome (the part of the genome formed by exons, the coding portions of genes that are expressed) or custom regions of interest is now available for biotech researchers using next-generation technology DNA sequencing protocols.


The new Roche NimbleGen (Madison, WI, USA) "SeqCap EZ Exome Plus Library" enables researchers to create their own target enrichment discovery tools by adding up to 50 Mb of custom targets to the existing 64 Mb EZ Exome v3 products providing the ability to target and enrich up to 114 Mb of total genomic DNA.

NimbelGen’s SeqCap EZ Library is a liquid-based enrichment technology, which enables the targeted capture for subsequent sequencing of the exome or a targeted subset of genes. More...
SeqCap EZ Library is compatible with various sequencing chemistries and with the addition of the Caliper Sciclone NGS Workstation, provides a comprehensive high-throughput target enrichment solution. Caliper Life Sciences (Hopkinton, MA, USA) is a leading provider of innovative liquid handling and microfluidic systems and has broad expertise in automating the processes involved in these core areas of genomics research including: extraction and purification, PCR reaction setup, automation of RT (real time)-PCR as well as the separation and direct detection of DNA and RNA.

In addition to the SeqCap EZ Library Roche NimbleGen has released new disease-specific target enrichment panels for clinical research applications. These include the SeqCap EZ Comprehensive Cancer Design, which covers 578 genes implicated in a wide range of common and rare cancers, and the SeqCap EZ Neurology Panel Design, which covers 256 genes associated with 87 neurological disorders, including Parkinson’s disease, Alzheimer’s disease, epilepsy, and autism.


“We are extremely excited to expand our targeted sequencing portfolio to meet the rapidly evolving needs of researchers in the field of next-generation sequencing,” said Thomas Schinecker, head of sequencing solutions at Roche NimbleGen. “Our proven industry leading performance in target enrichment technology gives us a strong foundation to offer these new solutions to researchers in basic research and translational research laboratories. In addition, we are looking forward into early next year when we will be launching new SeqCap EZ Reagents to provide customers with additional workflow convenience.”

Related Links:
Roche NimbleGen
Caliper Life Sciences



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.